STERIS plc

Análisis de la acción STERIS plc (STE)

$232.150

-0.070 (-0.03%)Al cierre

Loading chart…
Máximo
233.140
Apertura
230.790
Precio medio ponderado por volumen
231.56
Volumen
564.65K
Capitalización
21.40B
Mínimo
229.390
Importe
130.75M
EV/EBITDA, TTM
13.54

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

www.steris.com

Análisis de IA of STERIS plc (STE)

Comprar

STERIS plc is a good buy right now due to its current price of $232.15, which is below the analyst price target of $275 from UBS, indicating a potential upside of 18.5%. Additionally, the company has shown a strong gross margin of 43.89% in Q4 2026, demonstrating solid profitability. The main risk is the RSI at 76.92, indicating that the stock may be overbought in the short term, but the overall fundamentals and growth outlook support a long-term investment.

Recomendaciones de analistas (8)

Comprar
6 Comprar
2 Mantener
0 Vender
Actual: 232.15
Mínimo
—
Promedio
—
Máximo
—

UBS

2026-07-28

Precio objetivo

$275

Comprar

KeyBanc

2026-05-13

Precio objetivo

$269

Sobreponderar

Morgan Stanley

2026-01-08

Precio objetivo

—

Equal Weight

JPMorgan

2025-12-05

Precio objetivo

—

Neutral

KeyBanc

2025-07-22

Precio objetivo

$288

Sobreponderar

Métricas de valoración

El PER previsto actual de STERIS plc (STE) es 19.16, frente a su media de 5 años de 23.74.

PER previsto

Infravalorado
Media 5A P/E
23.74
P/E actual
19.16
Sobrevalorada
26.48
Infravalorada
21.00

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
16.14
EV/EBITDA actual
13.54
Sobrevalorada
18.53
Infravalorada
13.76

Precio/ventas previsto

Infravalorado
Media 5A P/S
3.91
P/S actual
3.34
Sobrevalorada
4.37
Infravalorada
3.45

Escenarios de precio de Alphio AI para STE

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%STE

$245.24

Precio del escenario

B

Base

Base · 50%STE

$207.79

Precio del escenario

B

Bajista

Bajista · 25%STE

$150.35

Precio del escenario

Ballenas con STE en cartera

C

Campbell & Company, LP

+ Con en carteraSTE

+9.56%

Rentabilidad a 3 meses

W

Williams Jones Wealth Management, LLC

+ Con en carteraSTE

+2.99%

Rentabilidad a 3 meses

L

Locust Wood Capital Advisers, LLC

+ Con en carteraSTE

+1.89%

Rentabilidad a 3 meses

F

Fenimore Asset Management, Inc.

+ Con en carteraSTE

-0.58%

Rentabilidad a 3 meses

G

GHP Investment Advisors, Inc.

+ Con en carteraSTE

-4.52%

Rentabilidad a 3 meses

F

Findlay Park Partners LLP

+ Con en carteraSTE

-7.98%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-12 (ET)

15:00:00

Steris Acquires Xodus Medical

2026-08-05 (ET)

09:31:00

Steris Invests $600M to Build Manufacturing Center in North Carolina

2026-07-30 (ET)

17:00:00

Steris Announces Quarterly Dividend of 69 Cents per Share

2026-05-11 (ET)

16:40:00

Company Reports Q4 Revenue of $1.6B

16:40:00

Sees FY27 Revenue Growth 7%-8% from $5.9B

Noticias

Preguntas frecuentes sobre STE, respondidas por Alphio AI

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

STERIS plc is a good buy right now due to its current price of $232.15, which is below the analyst price target of $275 from UBS, indicating a potential upside of 18.5%. Additionally, the company has shown a strong gross margin of 43.89% in Q4 2026, demonstrating solid profitability. The main risk is the RSI at 76.92, indicating that the stock may be overbought in the short term, but the overall fundamentals and growth outlook support a long-term investment.

8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar